Zhang Meimei and Liang Yi*
Volume3-Issue2
Dates: Received: 2022-01-17 | Accepted: 2022-01-31 | Published: 2022-02-01
Pages: 140-145
Abstract
Objective: To refer to the legislative basis and practice of compulsory licensing of drug patents in developed countries, based on the current situation of compulsory licensing of pharmaceutical patents in China, and to improve the research on compulsory licensing of pharmaceutical patents in China.
Methods: Understand the development status of drug patent licensing at home and abroad, compare and analyze domestic and foreign countries from the aspects of applicable conditions and practical measures, summarize the existing problems of compulsory licensing of drug patents in China, and put forward targeted improvement suggestions.
Results: Compared with foreign legislative foundations and practices, China's compulsory licensing system for drug patents lacks operability, and there are still great deficiencies and room for improvement in terms of applicable conditions and practical operations.
Conclusion: First, clarify the reasons for the application in the patent law and regulation system, expand the scope of applicable drugs, cancel the restrictions on the subject of the application, and shorten the judicial review period for the compulsory licensing of drug patents; secondly, improve the quality assurance and relief mechanism of the compulsory licensing drugs to protect the vital interests of patients; and finally, be good at using the deterrent power of the compulsory licensing system for drug patents.
FullText HTML
FullText PDF
DOI: 10.37871/jbres1411
Certificate of Publication
Copyright
© 2022 Meimei Z, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Meimei Z, Yi L. The Implementation Status and Improvement Suggestions of Drug Patent Compulsory Licensing in China-Based on the COVID-19 Pandemic. J Biomed Res Environ Sci. 2022 Feb 01; 3(2): 140-145. doi: 10.37871/jbres1411, Article ID: JBRES1411, Available at: https://www.jelsciences.com/articles/jbres1411.pdf
Subject area(s)
References
- Archita Sarmah, Domenico De Giovanni, Pietro De Giovanni. Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies. Eur J Oper Res. 2020;282(3):1053-1069. doi: 10.1016/j.ejor.2019.10.021.
- Wang J. The system defects and reform ideas of compulsory licensing of pharmaceutical patents in China. Journal of Qingdao University of Science and Technology. 2021;37(04):63-69. doi: 10.16800/j.cnki.jqustss.2021.04.010.
- Huang L. Inadequacy of China’s legislation on compulsory licensing of pharmaceutics patent and its improvement. Law Science Magazine. 2012;33(5):92-97. doi: 10.1692/j.cnki.1001-618x.2012.05.020.
- Huang L. The practice of compulsory licensing of patents in the United States and its implications for China. Wuhan University Journal (Philosophy & Social Science). 2012;65(03):65-69.
- Zi P. The U.S. FDA urgently approved influenza drugs and diagnostic reagents for the treatment of influenza A(H1N1). China Medical News. 2009;(10):17-17.
- Europe Patent Office [Internet]. Compulsory licensing in Europe; c2018 [cited 2022 January 13]. https://bit.ly/3GgICPM
- Peter Drahos. A philosophy of intellectual property [M]. Dartmouth. 1996;223.
